House dust mite allergen-specific adaptive immune repertoire (HDM-specific immune repertoire)

The house dust mite (HDM) allergen-specific adaptive immune repertoire refers to the diverse collection of T-cell receptors (TCRs) and B-cell receptors (BCRs) that recognize antigens from Dermatophagoides species, such as Der p 1 and Der p 2 (Source: PubMed, PMID: 31254570). In sensitized individuals, this repertoire is pathologically skewed toward a Th2-polarized T-cell response and the production of allergen-specific IgE antibodies, which trigger mast cell degranulation and chronic inflammation (Source: JACI, 2020). These immune components are central to the development of allergic asthma, rhinitis, and atopic dermatitis. While not a single molecular target, the repertoire is the primary focus of allergen-specific immunotherapy (ASIT), which seeks to induce immune tolerance by expanding regulatory T cells (Tregs) and shifting antibody production toward protective IgG4 (Source: NIH, NIAID). Modern therapeutic approaches also include biologics like Omalizumab, which neutralizes the IgE products of this repertoire, and Dupilumab, which inhibits the IL-4/IL-13 signaling required for its maintenance (Source: FDA). Monitoring the repertoire's diversity and clonal expansion via high-throughput sequencing is increasingly used as a biomarker for treatment efficacy and patient stratification in clinical trials (Source: Nature Communications, 2018).

Other names

HDM-specific TCR repertoireHDM-specific BCR repertoireHouse dust mite-specific T-cell and B-cell receptorsHDM-specific immunoglobulin repertoire

Allergen-specific immunotherapy (ASIT) induces immune tolerance by shifting the repertoire from a Th2/IgE-dominated response to a Treg/IgG4-dominated response (Source: PubMed, PMID: 28214150).